ZeroPoint Technologies and Rebellions forge strategic alliance to enhance AI accelerator performance and efficiency
Monash University, Australia's largest university and a top 50 global institution with presence across the Indo-Pacific, Europe, and the US, has announced a strategic partnership with ClinChoice, a global clinical-stage contract research organization. The collaboration combines Monash University's internationally recognized research excellence and clinical ecosystem with ClinChoice's global development, regulatory, and data science capabilities to support high-quality, patient-centric research across Australia and the broader international research landscape, with a particular focus on accelerating early-phase clinical development and bringing innovative therapies to patients faster.
Monash brings substantial clinical infrastructure to the partnership. The university is part of Australia's largest clinical trial network, spanning five major affiliated health services with more than 7,000 hospital beds and a national network of more than 3,000 GPs. Monash University-led trials account for around a quarter of all clinical trial activity in Australia, reaching a patient population of 4.5 million people. The university ranks in the world's top 50 universities in the QS World University Rankings 2026, QS Sustainability Rankings 2026, and US News and World Report Best Global Universities Rankings 2025-26, with particular distinction in pharmaceutical sciences—ranked third internationally in Pharmacy and Pharmaceutical Sciences and fourth in Pharmacy and Pharmacology.
The partnership was welcomed by institutional leadership. Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise), stated: "Monash is deeply committed to pursuing impact-driven partnerships that leverage our expertise in research and healthcare innovation. We're proud to partner with ClinChoice. By combining our research excellence with their global capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector." Kevin Xu, Chairman and CEO of ClinChoice, added: "We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science. This collaboration is a strong testament to ClinChoice's mission to support innovation through academic and clinical partnerships."
Kerry Dyson, President of International Clinical Operations at ClinChoice, emphasized the operational benefits: "By combining our global development experience with Monash's research excellence, we will advance clinical research in an even more efficient and impactful manner, ultimately bringing new therapies to patients faster." Monash's research capabilities are anchored in the world-renowned Monash Institute of Pharmaceutical Sciences (MIPS), which drives breakthrough innovations from target identification through preclinical and translational development, integrating fundamental science with strong industry collaboration to translate research into real-world healthcare outcomes.
ClinChoice brings complementary global expertise to the partnership. With more than 30 years of experience and operations spanning over 15 countries across North America, Europe, and Indo/Asia-Pacific, the organization brings deep therapeutic expertise in hematology/oncology, immunology and inflammation, cardiometabolics, and CNS. Having delivered more than 3,000 studies globally, ClinChoice has a strong track record of working with biopharmaceutical companies worldwide, delivering both early-phase and late-stage programs with speed, quality, and innovation.